in ,

Persons Infected with Novel Coronavirus May be ‘Symptom-Free’ for 5 Days

This scanning electron microscope image shows SARS-CoV-2 —previously known as 2019-nCoV, the virus that causes COVID-19. Credit: NIAID-RML

Research published this week in the Annals of Internal Medicine suggests that persons infected with SARS-CoV-2, the newly-identified virus that causes coronavirus disease COVID-19, may be symptom-free for about 5 days on average, and should expect to experience symptoms within 12 days.

The findings support current recommendations by the US Centers for Disease Control and Prevention (CDC) to actively monitor patients for 14 days after an assumed exposure to SARS-CoV-2 and have important implications for informing control activities.

Researchers from Johns Hopkins Bloomberg School of Public Health conducted an analysis of news reports, public health reports, and press releases from 50 provinces, regions, and countries outside of Wuhan, China to estimate the length of the incubation period of COVID-19, the time from exposure to symptom onset. They found information on 181 confirmed cases with identifiable exposure and symptom onset windows.

Based on the available data, the researchers estimated the median incubation period of COVID-19 to be 5.1 days and 97.5 percent of those who develop symptoms appeared to do so within 11.5 days of infection. These estimates imply that, under conservative assumptions, 101 out of every 10,000 cases will develop symptoms after 14 days of active monitoring or quarantine, which supports current CDC recommendations.

The authors caution that given recent evidence of SARS-CoV-2 transmission by mildly symptomatic and asymptomatic individuals, time from exposure to onset of infectiousness (latent period) may be shorter than the estimated incubation period, with important implications for transmission dynamics.


This information is not intended as medical advice or clinician guidance. This content contains edited excerpts to bring attention to the work of the researchers and study authors. Please support their efforts and click through for the full context.

An Ambitious Goal: Reducing Biothreats and Making Bioweapons Obsolete

BARDA Backs Holigic’s High-Throughput COVID-19 Diagnostic